Northwire Canada EditionThursday, July 23, 2026
Sign inSubscribe
Northwire
⌕
TECK 83.26 +3.2% FVI 11.90 −1.6% SUM 1.31 −1.5% RSMX 0.105 −4.5% STW 0.105 +5.0% PAT 0.250 +0.0% CCM 0.530 +1.9% SGN 0.250 −2.0% CNC 1.48 +0.7% PHNM 0.340 +4.6% LIO 0.160 +0.0% RIO 2.67 −4.1% KG 0.160 +3.2% GEN 0.065 +0.0% ECU 1.64 +8.6% ALTA 0.170 −2.9% TECK 83.26 +3.2% FVI 11.90 −1.6% SUM 1.31 −1.5% RSMX 0.105 −4.5% STW 0.105 +5.0% PAT 0.250 +0.0% CCM 0.530 +1.9% SGN 0.250 −2.0% CNC 1.48 +0.7% PHNM 0.340 +4.6% LIO 0.160 +0.0% RIO 2.67 −4.1% KG 0.160 +3.2% GEN 0.065 +0.0% ECU 1.64 +8.6% ALTA 0.170 −2.9%
Earnings

Perimeter estimates Q2 2025 revenue of $500,000 (U.S.)

By The Northwire Desk — AI Analysis Aug 11, 2025 · 19:01 PINK · 0.255 Perimeter Medical Imaging AI Inc
PINK · Price

Executive Summary

  • Perimeter Medical Imaging AI Inc. released preliminary unaudited revenue guidance for Q2 2025, anticipating approximately $500,000 in revenue, representing ~100% year-over-year growth and >50% sequential recurring revenue growth.
  • The company expects total operating costs to decrease by approximately 30% starting in Q3 2025 due to cost control efforts.
  • The release coincides with significant management changes, including the appointment of new VPs for Sales and Corporate Development, and the retirement of the COO.

Key Details

  • Q2 2025 Revenue Guidance: Anticipated total revenue of approximately $500,000.
  • Year-over-Year Growth: Revenue expected to grow by approximately 100% compared to Q2 2024.
  • Sequential Growth: Greater-than-35% procedure growth expected, driving over-50% recurring revenue growth compared to Q1 2025.
  • Six-Month Revenue Guidance: Total revenue for the six months ended June 30, 2025, expected to be approximately $1.0 million (compared to $345,000 in the same period in 2024 and $846,000 for the full year 2024).
  • Gross Margin: Expected to be approximately 69% for Q2 2025 and 61% for the six-month period ended June 30, 2025.
  • Cost Reduction: Total operating costs expected to reduce by ~30% starting in Q3 2025.
  • Operational Drivers: Growth driven by stronger S-Series system utilization, more interoperative OTC imaging procedures, and higher price per procedure.
  • Product Pipeline: Premarket approval application for the next-generation Perimeter B-Series is under review with the FDA.

Notable Quotes

  • "We are excited that the growing adoption, both in terms of new system placements and increased current device utilization, we saw during the first three months of the year continued through the second quarter... six-month 2025 revenue alone is estimated to surpass revenues for all of 2024." — Adrian Mendes, CEO
  • "We are excited to welcome Abbey and Paolo to the Perimeter team. They bring deep expertise and leadership that will be critical as we advance our business." — Adrian Mendes, CEO
Read the original news release →

More from Perimeter Medical Imaging AI Inc

Jun 09, 2026 · 09:05

FDA-approved AI surgical imaging pioneer secures minor R&D grant as commercial ramp remains early-stage and cash-burn persists

Other May 28, 2026 · 16:40

Perimeter Medical Imaging AI

Earnings Apr 29, 2026 · 08:00

Perimeter Showcases FDA-Approved Claire System at ASBrS 2026

Other Apr 28, 2026 · 08:15

CEO Insider Commitment Validates FDA Milestone But Dilution Concerns Persist Amidst Consolidation

Financings Apr 21, 2026 · 07:15

Perimeter Medical Imaging AI Secures Lifeline Financing at Discount to Market Price Amidst Cash Burn Concerns

Financings Mar 31, 2026 · 16:15

Perimeter Clears FDA Hurdle and Posts Record Sales, But Cash Runway and Dilution Threaten Near-Term Upside

Earnings